Although prostate cancer metastasis to the bone is predominantly osteoblastic, and the humoral hypercalcemia of malignancy syndrome in the patients is atypical, the canonical activation of parathyroid hormone-related peptide (PTHrP) production by CaSR, which is characteristic of osteoclastic metastasis—for example, in breast and lung cancer—still appears to be relevant [180]. Here, PTHLH is linked to prostate cancer.